All In Biotech

Drug Trial Radar · NCT06787612

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Multi-Arm Phase 2 Platform Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 397 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

397

Planned (sponsor's estimate)

Start

May 28, 2025

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jan 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab, REGN10597 and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations

Conditions

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer

Interventions

  • UbamatamabDrug

    Administered per the protocol

  • BevacizumabDrug

    Administered per the protocol

  • CemiplimabDrug

    Administered per the protocol

  • FianlimabDrug

    Administered per the protocol

  • PLDDrug

    Administered per the protocol

  • SarilumabDrug

    Administered per the protocol

  • REGN10597Drug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessmentTime frame: Up to 3 years

Locations

56 sites in 5 countries. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • UC San Diego Health

    La Jolla, California · Recruiting

  • Cedars Sinai Medical Center

    Los Angeles, California · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Advent Health Cancer Institute

    Orlando, Florida · Recruiting

  • Tampa General Hospital Cancer Institute

    Tampa, Florida · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • The University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • Norton Cancer Institute, St. Matthews Clinic

    Louisville, Kentucky · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • The Ohio State University Comprehensive Cancer Center

    Hilliard, Ohio · Recruiting

  • Providence Cancer Institute

    Portland, Oregon · Recruiting

  • University of Pittsburgh Medical Center, Magee-Womens Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • West Penn Hospital of Allegheny Health Network

    Pittsburgh, Pennsylvania · Recruiting

  • Avera Cancer Institute Sioux Falls

    Sioux Falls, South Dakota · Recruiting

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Swedish Cancer Institute

    Seattle, Washington · Recruiting

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • Centre Hospitalier Universitaire (CHU) de Quebec - Universite Laval

    Québec, Canada · Recruiting

  • CancerCare Manitoba

    Winnipeg, Manitoba, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Centre de Santé et de Services Sociaux de la Montérégie-Centre

    Greenfield Park, Quebec, Canada · Recruiting

  • Jewish General Hospital

    Montreal, Quebec, Canada · Recruiting

  • Research Institute - McGill University Health Centre

    Montreal, Quebec, Canada · Recruiting

  • Keimyung University Dongsan Hospital

    Daegu, South Korea · Recruiting

  • Severance Hospital Yonsei University Health System

    Seoul, South Korea · Recruiting

  • Asan Medical Center, Univ. of Ulsan

    Seoul, South Korea · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Gangnam Severance Hospital

    Seoul, South Korea · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Korea University Guro Hospital

    Seoul, South Korea · Recruiting

  • National Cancer Center

    Gyeonggi-do, Gyeonggi-do, South Korea · Recruiting

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea · Recruiting

  • Gachon University Gil Medical Center

    Incheon, Seoul, South Korea · Recruiting

  • Chi Mei Medical Center

    Tainan, Taiwan · Recruiting

  • Mackay Memorial Hospital

    Taipei, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.